OACC on Nasdaq
Oaktree Acquisition Corp. III Life Sciences
Blank check company in the Cayman Islands, incorporated in the Cayman Islands. Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
- TickerOACC on Nasdaq1
- IndustryBlank Checks1
- HeadquartersLos Angeles, California1
- Incorporated inCayman Islands3
- Business address333 South Grand Avenue, 28Th Floor, Los Angeles, Ca 900713
- Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company3
See how the biggest companies compare on our leaderboards
We are a newly organized blank check company incorporated on June 28, 2024, as a Cayman Islands exempted company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this Report as our initial business combination. To date, our efforts have been limited to organizational activities, activities related to our initial public offering and our search for an initial business combination. We have not selected any specific business combination target yet. We have generated no operating revenues to date and we do not expect that we will generate operating revenues until we consummate our initial business combination.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement as filed: the last 1 fiscal year, latest first.2
| Period ending | 2025-12-31 |
|---|---|
| General and administrative expenses | $1.2M |
| Loss from operations | -$1.2M |
| Change in fair value of over-allotment liability | $0 |
| Interest earned on cash held in Trust Account | $8.5M |
| Total other income | $8.5M |
| Net income | $7.3M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2024-06-30 |
|---|---|---|---|
| Cash | $1.4M | $1.4M | |
| Prepaid expenses | $113.3K | $201.3K | |
| Total current assets | $1.5M | $1.6M | |
| Long-term prepaid insurance | $0 | $113.3K | |
| Cash held in Trust Account | $201.6M | $193.6M | |
| TOTAL ASSETS | $203.1M | $195.3M | |
| Accounts payable and accrued expenses | $502.0K | $535.5K | |
| Accrued offering costs | $0 | $180.0K | |
| Due to related party | $785.9K | $0 | |
| Promissory note - related party | $11.8K | $11.8K | |
| Total current liabilities | $1.3M | $727.3K | |
| Deferred legal fees | $299.1K | $299.1K | |
| Deferred underwriting fee payable | $6.7M | $6.7M | |
| Total Liabilities | $8.3M | $7.7M | |
| Class A ordinary shares subject to possible redemption, $0.0001 par value; 19,199,029 issued and outstanding as of December 31, 2025 and 2024; at redemption value of $10.50 and $10.08 per share as of December 31, 2025 and 2024, respectively | $201.6M | $193.6M | |
| Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding as of December 31, 2025 and 2024 | $0 | $0 | |
| Additional paid-in capital | $0 | $0 | |
| Accumulated deficit | -$6.8M | -$6.1M | |
| Total Shareholders' Deficit | -$6.8M | -$6.1M | $0 |
| TOTAL LIABILITIES, CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION AND SHAREHOLDERS' DEFICIT | $203.1M | $195.3M | |
| Preferred stock, par or stated value per share | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 1.0M shares | 1.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2024-06-30 |
|---|---|---|---|
| Cash | $1.4M | $1.4M | |
| Prepaid expenses | $113.3K | $201.3K | |
| Total current assets | $1.5M | $1.6M | |
| Long-term prepaid insurance | $0 | $113.3K | |
| Cash held in Trust Account | $201.6M | $193.6M | |
| TOTAL ASSETS | $203.1M | $195.3M | |
| Accounts payable and accrued expenses | $502.0K | $535.5K | |
| Accrued offering costs | $0 | $180.0K | |
| Due to related party | $785.9K | $0 | |
| Promissory note - related party | $11.8K | $11.8K | |
| Total current liabilities | $1.3M | $727.3K | |
| Deferred legal fees | $299.1K | $299.1K | |
| Deferred underwriting fee payable | $6.7M | $6.7M | |
| Total Liabilities | $8.3M | $7.7M | |
| Class A ordinary shares subject to possible redemption, $0.0001 par value; 19,199,029 issued and outstanding as of December 31, 2025 and 2024; at redemption value of $10.50 and $10.08 per share as of December 31, 2025 and 2024, respectively | $201.6M | $193.6M | |
| Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding as of December 31, 2025 and 2024 | $0 | $0 | |
| Additional paid-in capital | $0 | $0 | |
| Accumulated deficit | -$6.8M | -$6.1M | |
| Total Shareholders' Deficit | -$6.8M | -$6.1M | $0 |
| TOTAL LIABILITIES, CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION AND SHAREHOLDERS' DEFICIT | $203.1M | $195.3M | |
| Preferred stock, par or stated value per share | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 1.0M shares | 1.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 1 fiscal year, latest first.2
| Period ending | 2025-12-31 |
|---|---|
| Net Income (Loss) | $7.3M |
| Interest earned on cash held in Trust Account | -$8.5M |
| Change in fair value of over-allotment liability | $0 |
| Payment of operating costs through promissory note | $0 |
| Prepaid expenses | $88.0K |
| Long Term prepaid insurance | $113.3K |
| Accounts payable and accrued expenses | -$33.5K |
| Accrued offering costs | -$180.0K |
| Due to related party | $785.9K |
| Net cash used in operating activities | -$422.1K |
| Investment of cash in Trust Account | $0 |
| Cash withdrawn from Trust Account for allowable working capital purposes | $500.0K |
| Net cash provided by investing activities | $500.0K |
| Proceeds from sale of Units, net of underwriting discounts paid | $0 |
| Proceeds from sale of Private Placement Units | $0 |
| Repayment of promissory noterelated party | $0 |
| Net cash provided by financing activities | $0 |
| Net Change in Cash | $77.9K |
| Offering costs included in accrued offering costs | $0 |
| Deferred offering costs paid by Sponsor in exchange for issuance of Class B ordinary shares | $0 |
| Deferred offering costs paid through promissory noterelated party | $0 |
| Prepaid services contributed by Sponsor through promissory noterelated party | $0 |
| Deferred underwriting fee payable | $0 |
| Deferred legal fee payable | $0 |
| Forfeiture of Founder Shares | $0 |
No quarter-by-quarter statement was filed.
Compare Oaktree Acquisition Corp. III Life Sciences with another company
Leadership
Who has led Oaktree Acquisition Corp. III Life Sciences, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
- Chief executive officerZaid Pardesi Oct 23, 2024 to now9
- Chief financial officerCourtney Conigliaro Oct 23, 2024 to now10
- Chief operating officerMathew Pendo Oct 23, 2024 to now11
Board members and other officers (4)
- Board memberAlvin Shih Oct 23, 2024 to now12
- Board memberAman Kumar Oct 23, 2024 to now13
- Board memberJohn B. Frank Oct 23, 2024 to now14
- Board memberPaul M. Meister Oct 23, 2024 to now15
Timeline
- Oct 23, 2024New chief executive Zaid Pardesi becomes CEO9
Filings
60 filings to the SEC since October 2021: 2 annual reports, 5 quarterly reports, 9 major events, 12 insider forms, 13 large holders, 19 other. The latest 20:
- Oct 15, 2026DEFA14A EDGAR
- Oct 15, 20268-K EDGAR
- Oct 2, 2026DEF 14A EDGAR
- Sep 21, 2026PRE 14A EDGAR
- Aug 14, 2026SCHEDULE 13G EDGAR
- Aug 13, 2026SCHEDULE 13G EDGAR
- Aug 12, 202610-Q EDGAR
- May 15, 2026SCHEDULE 13G EDGAR
- May 13, 202610-Q EDGAR
- May 11, 2026SCHEDULE 13G EDGAR
- Mar 26, 202610-K EDGAR
- Feb 11, 2026SCHEDULE 13G/A EDGAR
- Nov 13, 202510-Q EDGAR
- Oct 29, 20253 EDGAR
- Oct 29, 20258-K EDGAR
- Oct 22, 20253 EDGAR
- Oct 17, 20258-K EDGAR
- Aug 12, 202510-Q EDGAR
- Jul 15, 2025SCHEDULE 13G/A EDGAR
- Jun 16, 20253 EDGAR
The 60 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Decagon Asset Management LLPSCHEDULE 13G, 1 filing Aug 14, 202616
- BarclaysSCHEDULE 13G, 3 filings May 13, 2025 to Aug 13, 202617
- Fort Baker Capital Management LPSCHEDULE 13G, 1 filing May 15, 202618
- Goldman SachsSCHEDULE 13G, 1 filing May 11, 202619
- MILLENNIUM MANAGEMENT LLCSCHEDULE 13G/A, 2 filings Oct 30, 2024 to Jul 15, 202520
- AQR CAPITAL MANAGEMENT LLCSCHEDULE 13G/A, 2 filings Nov 7, 2024 to May 14, 202521
- HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUNDSCHEDULE 13G/A, 2 filings Feb 14, 2025 to May 14, 202522
- Oaktree Acquisition Holdings III LS, LLCSCHEDULE 13G, 1 filing Feb 12, 202523
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12SEC EDGARAlvin Shih, Board member
- 13SEC EDGARAman Kumar, Board member
- 14SEC EDGARJohn B. Frank, Board member
- 15SEC EDGARPaul M. Meister, Board member
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23